Concepedia

Author

René Verloes

Janssen (Belgium)

Also Known As

R VERLOES, R Verloes, R. VERLOES, R. Verloes, R.A.L. Verloes, RENÉ VERLOES, Rene Verloes, Rene´ Verloes, René Verloes

56

Publications

1.1K

Citations

15

H-Index

46

Concepts

All Affiliations

Janssen (Belgium)Charité - Universitätsmedizin BerlinUniversité Libre de BruxellesAmsterdam UMC Location University of AmsterdamMedical University of Białystok
RV

About

René Verloes is an author at Janssen (Belgium) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

15

640

2

Social Sciences

2

2

74

3

Health Sciences

1

1

16

4

Anesthesia

1

1

15

5

Biochemistry

1

1

16

René Verloes

×

22

Publications

975

Citations

15

H-Index

YearCitations

ucb L059, a novel anti-convulsant drug: pharmacological profile in animais

Alma J. Gower, Michel Noyer, René Verloes,

European Journal of Pharmacology

1992

213

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

H. W. Reesink, Gregory Fanning, Khalid Abou Farha,

Gastroenterology

2009

155

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study

Marita Stevens, Sarah Rusch, John P. DeVincenzo,

The Journal of Infectious Diseases

2018

81

Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial

Michael P. Manns, H. W. Reesink, Thomas Berg,

Antiviral Therapy

2011

66

Effects of nootropic drugs in a scopolamine-induced amnesia model in mice

René Verloes, A.-M. Scotto, J.G. Gobert,

Psychopharmacology

1988

59

Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model

Wieslawa Olszewska, Gabriela Ispas, Corinna Schnoeller,

European Respiratory Journal

2010

55

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long‐acting formulation in healthy volunteers

René Verloes, Sofie Deleu, Nico Niemeijer,

HIV Medicine

2015

52

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy

Oliver Lenz, Joep de Bruijne, Leen Vijgen,

Gastroenterology

2012

39

Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model

Gabriela Ispas, Anil Koul, Johan Verbeeck,

PLoS ONE

2015

39

11 OPERA-1 TRIAL: INTERIM ANALYSIS OF SAFETY AND ANTIVIRAL ACTIVITY OF TMC435 IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

M.P. Manns, H.W. Reesink, Christophe Moreno,

Journal of Hepatology

2009

25

Page 1